BH3 profiling to optimize lymphoma treatment: Pre-clinical studies

Myra Langendonk

    Onderzoeksoutput

    428 Downloads (Pure)

    Samenvatting

    Unfortunately, lymphoma (Hodgkin's and Non-Hodgkin's lymphoma) is still an incurable disease for many people and new and smart treatment techniques are needed to improve the prognosis of these patients.
    The goal of the research described in this dissertation was to find pre-existing medications used in other cancers, using a technique that allows to test the dependence on anti-apoptotic proteins (proteins important for the survival of cancer cells). This technique is called BH3 profiling.
    By applying this technique, it has been found that tamoxifen, an affordable, anti-hormone drug that has been used in breast cancer for more than 40 years, can kill lymph node cancer cells in laboratory experiments and in animal experimental models. If tamoxifen is combined with a drug that blocks anti-apoptotic proteins, the anticancer effect is enhanced. This has led to a clinical trial in patients with untreatable aggressive lymphoma.
    In addition to these important findings and applications, this thesis describes the efficacy of combinations of different drugs in lymphoma and whether these agents alter the dependence on these anti-apoptotic agents.
    This project was carried out through a KWF grant.
    Originele taal-2English
    KwalificatieDoctor of Philosophy
    Toekennende instantie
    • Rijksuniversiteit Groningen
    Begeleider(s)/adviseur
    • Huls, Gerwin, Supervisor
    • van den Berg, Anke, Supervisor
    • van Meerten, Tom, Co-supervisor
    • Visser, Lydia, Co-supervisor
    Datum van toekenning23-jun.-2023
    Plaats van publicatie[Groningen]
    Uitgever
    DOI's
    StatusPublished - 2023

    Vingerafdruk

    Duik in de onderzoeksthema's van 'BH3 profiling to optimize lymphoma treatment: Pre-clinical studies'. Samen vormen ze een unieke vingerafdruk.

    Citeer dit